CSIMarket
 


Seres Therapeutics Inc   (MCRB)
Other Ticker:  
 
 

MCRB's Revenue Growth by Quarter and Year

Seres Therapeutics Inc 's Revenue results by quarter and year




MCRB Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 0.98 7.22 17.56
III Quarter September 0.31 3.44 126.73 1.42
II Quarter June 126.47 1.22 5.26 6.05
I Quarter March -0.52 1.49 5.72 8.19
FY   126.26 7.13 144.93 33.22



MCRB Revenue third quarter 2023 Y/Y Growth Comment
Seres Therapeutics Inc reported drop in Revenue in the third quarter 2023 by -90.99% to $ 0.31 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Seres Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 738.21%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 230 other companies have achieved higher Revenue growth. While Seres Therapeutics Inc ' s Revenue meltdown of -90.99% ranks overall at the positon no. 3915 in the third quarter 2023.




MCRB Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -86.43 % -58.88 % 130.45 %
III Quarter September -90.99 % -97.29 % 8824.65 % -79.8 %
II Quarter June 10266.39 % -76.81 % -13.06 % -51.72 %
I Quarter March - -73.95 % -30.16 % 11.89 %
FY   - -95.08 % 336.27 % -3.71 %

Financial Statements
Seres Therapeutics Inc 's third quarter 2023 Revenue $ 0.31 millions MCRB's Income Statement
Seres Therapeutics Inc 's third quarter 2022 Revenue $ 3.44 millions Quarterly MCRB's Income Statement
New: More MCRB's historic Revenue Growth >>


MCRB Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -71.51 % -94.3 % 1136.62 %
III Quarter September -99.75 % 181.97 % 2309.32 % -76.53 %
II Quarter June - -18.12 % -8.04 % -26.13 %
I Quarter March - -79.36 % -67.43 % 7.48 %
FY (Year on Year)   - -95.08 % 336.27 % -3.71 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #231
Healthcare Sector #612
Overall #3915

Revenue Y/Y Growth Statistics
High Average Low
10300.74 % 738.21 % -97.28 %
(Jun 30 2023)   (Sep 30 2022)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #231
Healthcare Sector #612
Overall #3915
Revenue Y/Y Growth Statistics
High Average Low
10300.74 % 738.21 % -97.28 %
(Jun 30 2023)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Seres Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2307.85 % 146.58 % -99.75 %
(Sep 30 2021)  


MCRB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Seres Therapeutics Inc realized fall in Revenue sequentially by -99.75% to $ 0.31 millions, from $ 126.47 millions declared a quarter before.

Even seasonal factors were not able to rescue the III. Quarter for the Seres Therapeutics Inc , Antonio Ferrari, market contributor allocated in New York wrote.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Seres Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 949.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #95
Overall #949
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #95
Overall #949
Revenue Q/Q Growth Statistics
High Average Low
2307.85 % 146.58 % -99.75 %
(Sep 30 2021)  


MCRB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Seres Therapeutics Inc disclosed fall in Revenue from the previous quarter by -99.75% to $ 0.31 millions, from $ 126.47 millions released in the previous reporting period.

Some seasonal factors which usually energize III. Quarter 2023 performance, have not salvage the III. Quarter for the Seres Therapeutics Inc , Antonio Ferrari, market contributor allocated in New York said, he voiced little skepticism for the Seres Therapeutics Inc 's perspective and mentioned that average quarter on quarter Revenue growth is at 146.58% for MCRB.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Seres Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 949.


Seres Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 127.24 $ 130.37 $ 5.11 $ 7.13 $ 13.37
Y / Y Revenue Growth (TTM) 851.37 % -4.6 % -96.37 % -95.08 % -91.39 %
Year on Year Revenue Growth Overall Ranking # 926 # 19 # 95 # 61 # 2931
Seqeuential Revenue Change (TTM) -2.4 % 2449.78 % -28.27 % -46.7 % -90.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 3675 # 2686 # 2361 # 3004 # 3376




Cumulative Revenue growth Comment
With 851.37% annual Revenue growth, Seres Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 89 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 926.

Revenue TTM Q/Q Growth Statistics
High Average Low
851.37 %
97.29 %
-96.37 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 211
Healthcare Sector # 90
Overall # 926

Revenue TTM Y/Y Growth Statistics
High Average Low
851.37 %
97.29 %
-96.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 211
Sector # 557
S&P 500 # 3675
Cumulative Revenue growth Comment
With 851.37% annual Revenue growth, Seres Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2023.

In the Healthcare sector 89 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 926.

Revenue TTM Q/Q Growth Statistics
High Average Low
851.37 %
97.29 %
-96.37 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 211
Healthcare Sector # 90
Overall # 926

Revenue TTM Y/Y Growth Statistics
High Average Low
851.37 %
97.29 %
-96.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 211
Sector # 557
S&P 500 # 3675




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MCRB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MCRB's Competitors
Revenue Growth for Seres Therapeutics Inc 's Suppliers
Revenue Growth for MCRB's Customers

You may also want to know
MCRB's Annual Growth Rates MCRB's Profitability Ratios MCRB's Asset Turnover Ratio MCRB's Dividend Growth
MCRB's Roe MCRB's Valuation Ratios MCRB's Financial Strength Ratios MCRB's Dividend Payout Ratio
MCRB's Roa MCRB's Inventory Turnover Ratio MCRB's Growth Rates MCRB's Dividend Comparisons



Companies with similar Revenue surge for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc -0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com